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CLINICAL STUDIES ON THE TREATMENT OF
PROSTATIC CARCINOMA WITH ESTRAMUSTINE
       PHOSPHATE DISODIUM （ESTRACYT＠）
  Hideki YosHIDA， Kunio S田BAKI， Hajime OGAwA，
Makoto SHiMADA， Takao IKEuaHi and Kazuo IMAMuRA
From the l）ePartmentげ乙rrolog）， Shoωa Lfniversity School〔1プMedicine
             rエ）irector：1）プ（グ1（． Imamura M． D．ノ
    Estramustine phosphate disodium （Estracyt＠） was used in the treatment of 21 patients with pros－
tatic carcinoma in stage B， C and D． Sixteen patients were treated from the onset （primary treatment
group） and 5 had previously received some other antiandrogenic therapy （secondary treatment greup）．
The・drug was given oraily in a dose of 560Av840 mg／day for 3 menths， if tolerable． The clinical evalua－
tion was done after 3 months’ treatment． Recently it was reported that mortality from cardiovascular
complications ofpatients with prostatic cancer was greatest among those patients treated w’ith estrogens．
Therefore we studied also about the changes of serum cholesterol and triglyceride levels in the patients
undergoing treatment of Estracyt＠ in this report．
    The results were as follews：
    1） The remission of urination difliculties was observed in 78．6sOeoJ of t’he primary tr’eatrnent group
and in 40．OO／， of the secondary treatment group．
    2） The significant or moderate reduction of tumor of the prostate was shown ih 85．70／． of the
primary group and in 80．0 O／． of the secondary group．
    3） Elevated levels of serum acid phosphatase （total and prostatic） was decreased significantly
in the both groups．
    4） Over－all clinical－effect judged from the subjective and objective remissions was noted in 68．8％
of the primary treatment group and in 40．00／． of the secondary treatment group．
    5）Seru皿cholesterol levels decreased moderately， on the other hand， marked elevation of serum
triglyceride levels was observed in the 2nd months during the treatment with Estracyt＠．
    6） As for the general side－effects， gastrointestinal disorder was shown in 4 patients， and in one
ofthem we had to discontinue this medication． Elevation ofserum GO：［” and GPT ievels was transiently
．observed in 2 cases． Leukopenia was not observed．
    From these results， we considered that the clinical effect of Estracyt＠ for the patients with prostatic
carcinoma was very evaluable． Therapeutic effect can be expected even in the patients who had no
response to the previous treatment with some other antiandrogenic agents． The significant elevation
of the serum triglyceride levels during the treatment suggests us to take care of cardiovascular complica－
tion during long term treatment with Estracyt＠．
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  一般名：Estramustine phosphate disodium
Fig． L Estramustine phosphate disodiumの構造式
Tablc 1．新   鮮   例

































































































吉田・ほか・PC ・ Estracyt 855
Table 2．抵抗例
症 例  年 令 組織型 Stage 投与量（mg／日） 既 治 療
17 76 well diff． D 560 除睾十Hexron 30 mg．4M
18 72 well diff． D 560 除睾十Hysron 100mg．18M
19 75 well diff． D 560 除睾十Hexron 30 mg．12M
 －HysrQn 80 mg． 20M
20 55 poor difL D 560 除睾十Hexron 30 mg．9M
21 62 well diff． D 560 除睾十Hysron 100mg．5M























































 前立腺の触診所見の変化はTable 4 に示したよう
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Table 3．排尿状態に対する効果
症例数  改 善 やや改善 不 変
新 鮮 例 14 9 2 3
抵 抗 例 5 2 o 3
Table 4．触診所見の変化
症例数 著明縮小やや縮小不変 増大
新 鮮 例 14 6 6 2 o

















































     前1．M 2。M 3．M
Fig．3，総酸・フォスファターゼ値の変動（B－L． U）
















             ◎一・一〇：新鮮例
             ●一●：抵抗例































症例数  有 効 やや有効 無 効  有効率
560mg投与群 11 8 3 o 72．70／o
840mg投与群 5 3 1 1 60．0 o／o
Table 6．新鮮例と抵抗例との臨床的効果
症例数 有効やや有効無効 有効率
新鮮例 16 11 4 1 68．80／o
抵 抗 例 5 2 o 3 40 ．0 o／o
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Table 7． Stageによる臨床的効果判定
Stage症例数 有効やや有効無効臨床的有効率
B 3 2 1 o 66．70／o
新 鮮 例 。 7 6 i o 85．70／o
D 6 3 2 1 50，0e／o

























































（mean ± S． D）
  ／9／
WBC （O）
 前LM 2．M 3．M
Fig．5．赤血球数および白血球数の変動



































































     前1．M 2．M 3．M
Fig．6．新鮮例における血清総コレステロール値およ
    びトリグリセライド値の変動



















 estramustine phosphate disodium（Estracyt⑪）は
Figコにも示したように，ホルモン作用と抗腫瘍作用
の両方の作用が期待できる薬剤である．その基礎的研
   前1．M 2．M 3．M
Fig．7．乱840 mg／日投与群と560 mg／日投与群別
    による血清トリグリセテイド値の変動





















ついて，Forshell et al・13・14）およびSzendroi et al．15）
らは，cstramustine phosphateの消化管からの吸収は
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